Japan has begun post-approval use of an iPS-cell therapy for Parkinson’s, and the first transplant in a follow-up study was completed at Kyoto University Hospital in October.
Sumitomo Pharma developed the therapy, called AMCHEPRY, using cells from healthy donors that were developed into early forms of dopamine-producing brain cells, which are lost as Parkinson’s progresses. The company disclosed the transplant on October 30 but did not release detailed information about the patient or procedure. Japan granted the product conditional, time-limited approval in March 2026 for patients whose motor symptoms are not sufficiently controlled by existing medicines, including levodopa.
The approval followed an earlier Kyoto University trial in which seven people aged 50 to 69 received cell transplants and were monitored for two years. Researchers reported no serious adverse events. Four of the six patients assessed for motor improvement had better scores.
The study was small and did not hide which patients received treatment, so it cannot establish how well the therapy works for a wider population. The new transplant is part of clinical evaluation after approval, not the first time a person has received iPS-derived cells for Parkinson’s. The earlier trial involved seven recipients.
Sumitomo Pharma says further treatment and follow-up will be needed to build evidence about safety and effectiveness before full approval can be considered.